C
Castle Biosciences Inc (CSTL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
$33.79
-0.71 (-2.06%)
Market Cap: $1.04B
Last updated: Nov 17, 2026 at 11:05 AM ET
Castle Biosciences Inc (CSTL) Valuation Multiples
Castle Biosciences (CSTL) trades at 2.7x sales and 2.2x book value. Its P/S of 2.7x is in line with its 5-year median.
Current Multiples
Its free cash flow yield is 0.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 2.7x |
| Price to book | 2.2x |
| Price to FCF | 261.2x |
| EV/FCF | 244.1x |
| PEG | N/A |
| FCF yield | 0.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.7x | 2.7x | N/A |
| P/B | 2.2x | 1.6x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 2.3x in 2024 to 20.7x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $38.90 | N/A | 3.3x | 2.4x |
| 2024 | $26.65 | 43.0x | 2.3x | 1.8x |
| 2023 | $21.58 | N/A | 2.6x | 1.5x |
| 2022 | $23.54 | N/A | 4.5x | 1.6x |
| 2021 | $42.87 | N/A | 11.5x | 2.6x |
| 2020 | $67.15 | N/A | 20.7x | 3.4x |
| 2019 | $34.37 | N/A | 4.3x | 7.5x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CSTL
Is CSTL stock overvalued?
GNG's valuation label for CSTL is Overvalued.
What is CSTL's price to sales ratio?
Castle Biosciences has a price to sales ratio of 2.7x.
CSTL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts